Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Current Liabilities (2016 - 2025)

IGC Pharma has reported Total Current Liabilities over the past 15 years, most recently at $1.5 million for Q3 2025.

  • Quarterly Total Current Liabilities fell 45.97% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Sep 2025, down 45.97% year-over-year, with the annual reading at $2.3 million for FY2025, 3.55% down from the prior year.
  • Total Current Liabilities was $1.5 million for Q3 2025 at IGC Pharma, down from $1.7 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $2.8 million in Q3 2024 and troughed at $1.3 million in Q4 2021.
  • The 5-year median for Total Current Liabilities is $2.1 million (2023), against an average of $2.0 million.
  • Year-over-year, Total Current Liabilities surged 52.39% in 2023 and then plummeted 45.97% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $1.3 million in 2021, then grew by 6.02% to $1.4 million in 2022, then surged by 42.77% to $1.9 million in 2023, then skyrocketed by 37.24% to $2.7 million in 2024, then crashed by 43.02% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Current Liabilities are $1.5 million (Q3 2025), $1.7 million (Q2 2025), and $2.3 million (Q1 2025).